Zogenix Inc (ZGNX) Gross Profit Margin starting from the fourth quarter 2021 to fourth quarter 2020, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Zogenix Inc   (NASDAQ: ZGNX)


Zogenix Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ZGNX Gross Profit Margin (Dec 31 2021)
Q4 		(Sep 30 2021)
Q3 		(Jun 30 2021)
Q2 		(Mar 31 2021)
Q1 		(Dec 31 2020)
Q4
Y / Y Revenue Change 212.95 %
Seq. Revenue Change 17.68 %
Revenue In Millions $26.61
Gross Profit Margin 93.83 %
Gross Profit Margin Total Ranking # 208
Gross Profit In Millions $24.97
Y / Y Gross Profit Change -
Seq. Gross Profit Change 17.12 %


Commenting fourth quarter 2021 Gross Profit Margin
Zogenix Inc has managed to improve its Revenue sequentially to $26.61 millions by 17.68 % faster than Gross Profit increase of 17.12 % to $24.97 millions, this led to contraction in Gross Profit Margin to 93.83 %, but the Zogenix Inc IV. Quarter Gross Profit Margin remained above company average rate of 43.46%.


Observing fourth quarter 2021 results within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 168 to 208.
Learn about Gross Margin
ZGNX's Gross Profit Margin fourth quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 23
Healthcare Sector # 39
Overall # 200

Gross Profit Margin Statistics
High Average Low
95.1 % 43.46 % 1.29 %
(Sep 30 2020)   (Jun 30 2016)


ZGNX Gross Income Trends • More of ZGNX's Profitabilty Ratios • ZGNX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ZGNX's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ZGNX's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ZGNX's Competitors
Gross Profit Margin Profit Margin for Zogenix Inc 's Suppliers
Gross Profit Margin Profit Margin for ZGNX's Customers

You may also want to know
ZGNX's Annual Growth Rates ZGNX's Profitability Ratios ZGNX's Asset Turnover Ratio ZGNX's Dividend Growth
ZGNX's Roe ZGNX's Valuation Ratios ZGNX's Financial Strength Ratios ZGNX's Gross Profit Growth
ZGNX's Roa ZGNX's Inventory Turnover Ratio ZGNX's Growth Rates ZGNX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Gross Profit MarginDec 31 2021 MRQ Gross ProfitDec 31 2021 MRQ Revenue
Galapagos Nv  99.66 %$ 541.203  Millions$ 543.028  Millions
Ionis Pharmaceuticals Inc   99.49 %$ 437.779  Millions$ 440.006  Millions
Intercept Pharmaceuticals inc   98.90 %$ 91.390  Millions$ 92.404  Millions
Corcept Therapeutics Inc  98.63 %$ 97.468  Millions$ 98.822  Millions
Elicio Therapeutics Inc   98.28 %$ 24.702  Millions$ 25.135  Millions
Acadia Pharmaceuticals Inc   98.13 %$ 128.314  Millions$ 130.758  Millions
Aurinia Pharmaceuticals Inc   97.94 %$ 22.923  Millions$ 23.404  Millions
Global Blood Therapeutics Inc.  97.94 %$ 54.945  Millions$ 56.099  Millions
Deciphera Pharmaceuticals Inc   97.86 %$ 23.681  Millions$ 24.199  Millions
Zevra Therapeutics Inc   97.71 %$ 2.523  Millions$ 2.582  Millions
Rigel Pharmaceuticals Inc  97.61 %$ 19.922  Millions$ 20.409  Millions
Albireo Pharma inc   97.16 %$ 31.596  Millions$ 32.521  Millions
Uniqure N v   96.88 %$ 55.893  Millions$ 57.691  Millions
Travere Therapeutics Inc   96.69 %$ 55.353  Millions$ 57.249  Millions
Serina Therapeutics Inc   96.30 %$ 0.026  Millions$ 0.027  Millions
Adc Therapeutics Sa  95.89 %$ 32.524  Millions$ 33.917  Millions
Ultragenyx Pharmaceutical Inc   95.79 %$ 79.880  Millions$ 83.389  Millions
Hookipa Pharma inc   95.74 %$ 3.729  Millions$ 3.895  Millions
Eton Pharmaceuticals Inc   95.40 %$ 5.813  Millions$ 6.093  Millions
Sage Therapeutics Inc   94.70 %$ 1.555  Millions$ 1.642  Millions
Sinovac Biotech Ltd  94.47 %$ 18,302.683  Millions$ 19,374.904  Millions
Tg Therapeutics Inc   94.01 %$ 2.182  Millions$ 2.321  Millions
Zogenix Inc   93.83 %$ 24.965  Millions$ 26.607  Millions
Chemocentryx Inc.  93.48 %$ 4.328  Millions$ 4.630  Millions
Emergent Biosolutions Inc   93.41 %$ 684.600  Millions$ 732.900  Millions
Macrogenics Inc   93.31 %$ 13.200  Millions$ 14.147  Millions
Myovant Sciences Ltd   92.21 %$ 50.197  Millions$ 54.440  Millions
United Therapeutics Corporation  91.67 %$ 380.600  Millions$ 415.200  Millions
Ocular Therapeutix Inc   91.00 %$ 11.201  Millions$ 12.309  Millions
Bridgebio Pharma Inc   90.90 %$ 11.714  Millions$ 12.886  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.